Gilead Sciences, Inc. (NASDAQ:GILD) Position Lessened by Wealth Enhancement Advisory Services LLC

Wealth Enhancement Advisory Services LLC trimmed its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 4.0% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 252,954 shares of the biopharmaceutical company’s stock after selling 10,675 shares during the period. Wealth Enhancement Advisory Services LLC’s holdings in Gilead Sciences were worth $18,529,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also modified their holdings of the company. Procyon Advisors LLC raised its holdings in Gilead Sciences by 13.1% during the first quarter. Procyon Advisors LLC now owns 34,232 shares of the biopharmaceutical company’s stock valued at $2,507,000 after buying an additional 3,955 shares in the last quarter. DGS Capital Management LLC raised its holdings in Gilead Sciences by 13.1% during the first quarter. DGS Capital Management LLC now owns 8,809 shares of the biopharmaceutical company’s stock valued at $645,000 after buying an additional 1,021 shares in the last quarter. Matrix Asset Advisors Inc. NY grew its position in shares of Gilead Sciences by 4.8% in the first quarter. Matrix Asset Advisors Inc. NY now owns 311,545 shares of the biopharmaceutical company’s stock valued at $22,821,000 after purchasing an additional 14,200 shares during the last quarter. Future Financial Wealth Managment LLC acquired a new stake in shares of Gilead Sciences in the first quarter valued at about $161,000. Finally, Brookstone Capital Management grew its position in shares of Gilead Sciences by 751.1% in the first quarter. Brookstone Capital Management now owns 127,258 shares of the biopharmaceutical company’s stock valued at $9,322,000 after purchasing an additional 112,305 shares during the last quarter. 83.67% of the stock is currently owned by hedge funds and other institutional investors.

Gilead Sciences Stock Performance

Shares of NASDAQ:GILD opened at $68.85 on Friday. The company’s 50 day moving average price is $65.89 and its two-hundred day moving average price is $72.75. Gilead Sciences, Inc. has a 12-month low of $62.07 and a 12-month high of $87.86. The firm has a market cap of $85.78 billion, a PE ratio of 191.19, a PEG ratio of 2.95 and a beta of 0.20. The company has a quick ratio of 0.94, a current ratio of 1.08 and a debt-to-equity ratio of 1.31.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Thursday, April 25th. The biopharmaceutical company reported ($1.32) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.49) by $0.17. The business had revenue of $6.69 billion for the quarter, compared to analyst estimates of $6.36 billion. Gilead Sciences had a net margin of 1.76% and a return on equity of 24.34%. The firm’s revenue for the quarter was up 5.3% on a year-over-year basis. During the same quarter last year, the business posted $1.37 EPS. Equities research analysts predict that Gilead Sciences, Inc. will post 3.75 earnings per share for the current year.

Gilead Sciences Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Thursday, June 27th. Stockholders of record on Friday, June 14th were paid a dividend of $0.77 per share. This represents a $3.08 annualized dividend and a dividend yield of 4.47%. The ex-dividend date of this dividend was Friday, June 14th. Gilead Sciences’s payout ratio is currently 855.56%.

Wall Street Analyst Weigh In

GILD has been the topic of a number of recent research reports. Wells Fargo & Company decreased their target price on Gilead Sciences from $84.00 to $77.00 and set an “equal weight” rating on the stock in a research report on Monday, March 4th. Morgan Stanley cut their price target on shares of Gilead Sciences from $80.00 to $78.00 and set an “equal weight” rating for the company in a research note on Friday, April 26th. HSBC upgraded shares of Gilead Sciences from a “reduce” rating to a “hold” rating and set a $69.00 price target for the company in a research note on Wednesday, April 24th. StockNews.com upgraded shares of Gilead Sciences from a “buy” rating to a “strong-buy” rating in a research note on Saturday, April 27th. Finally, Oppenheimer restated an “outperform” rating and set a $105.00 price target on shares of Gilead Sciences in a research note on Friday, April 19th. Twelve investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, Gilead Sciences has a consensus rating of “Hold” and a consensus target price of $83.47.

Insider Buying and Selling

In related news, insider Merdad Parsey sold 2,000 shares of Gilead Sciences stock in a transaction on Monday, April 1st. The shares were sold at an average price of $72.96, for a total transaction of $145,920.00. Following the completion of the transaction, the insider now owns 96,304 shares of the company’s stock, valued at $7,026,339.84. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 0.16% of the stock is owned by insiders.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.